$0.095
-0.090 (-94.69%)At close
CERO Comparative Benchmarking
In the context of the broader market, CERO competes directly with industry leaders such as REVB and ADTX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CERO's gross margin of N/A stands against REVB's N/A and ADTX's 23.59%. Such benchmarking helps identify whether CERo Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.
Financials
FY2025Q2
YoY:
-8.24%
-4.72M
Operating Profit
FY2025Q2
YoY:
+121.24%
-5.42M
Net Income after Tax
FY2025Q2
YoY:
-71.35%
-61.71
EPS - Diluted
FY2022Q4
YoY:
-46.48%
-373.10K
Free Cash Flow
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.